Maze Therapeutics (MAZE) Accounts Payables (2024 - 2026)

Maze Therapeutics has disclosed Accounts Payables across 3 years of filings, most recently posting $4.0 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $4.0 million, up 66.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (up 66.93% YoY), and the FY2025 annual result was $1.8 million, down 7.48% from the prior year.
• Accounts Payables came in at $4.0 million for Q1 2026 at Maze Therapeutics, up from $1.8 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.0 million in Q1 2026 to a low of $1.8 million in Q4 2025.
• The 3-year median for Accounts Payables is $2.7 million (2025), against an average of $2.8 million.
• Across the five-year window, Accounts Payables fell 7.48% in 2025 and surged 66.93% in 2026, its largest moves.
• Maze Therapeutics' Accounts Payables stood at $1.9 million in 2024, then dropped by 7.48% to $1.8 million in 2025, then surged by 123.69% to $4.0 million in 2026.
• The last three Accounts Payables figures came in at $4.0 million (Q1 2026), $1.8 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.